Third Harmonic Bio will lay off half of its workforce, the biotech has said as it prepares to take its chronic spontaneous urticaria (CSU) candidate into phase 2. The company announced results for a ...

The Company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study in CSU by mid-year 2025. Key ...

1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to ...

THIRD HARMONIC BIO ($THRD) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.35 per share, missing estimates of -$0.30 by ...

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today ...

-- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE ...

Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- ...

Third Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolution. What Happened: Third Harmonic announced that its board approved and ...

After San Francisco biotech company Third Harmonic Bio slashed its staff by half in February, it’s now taking a more drastic step. The inflammatory disease research company’s directors have decided to ...

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data are ...